论文部分内容阅读
“我们希望通过这次重组,形成一个高水平的、有市场竞争力的医药产业平台” 2月,在上证指数围绕1300点震荡的时候,以华源制药为代表的“华源系”股票却联袂大涨,市场对“两华合璧”的消息作出了正面的反应。“两华”中的一华自然指麻烦缠身的华源集团,另一华指的则是在香港注册的央企华润集团。
“We hope that through this restructuring, we will form a platform for a high-level pharmaceutical industry with market competitiveness.” In February, when the Shanghai Composite Index fluctuated around 1300 points, Huayuan Pharmaceutical Co., Ltd. represented by Huayuan Pharmaceutical Rose side by side, the market reacted positively to the news of “combining two belligerents”. One of the “two China” naturally refers to the troublesome Huayuan Group, while the other refers to the central government-owned China Resources Group, which is registered in Hong Kong.